IQVIA a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the bioplatform innovation company, today announced a strategic collaboration

Camurus today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Oczyesa®, octreotide subcutaneous depot, marketing authorization

Travere Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for FILSPARI® (sparsentan),

Sandoz the global leader in generic and biosimilar medicines, today announced the launch of generic rivaroxaban in Germany, in new generic strengths of 10 mg, 15 mg and 20 mg. Rivaroxaban - 1 A Pharma® offers patients

MannKind Corporation and scPharmaceuticals Inc. (Nasdaq: SCPH) today announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals.

Genentech, a member of the Roche Group today broke ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility

Crinetics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling

Madrigal Pharmaceuticals, Inc, a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the European Commission (EC)